GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community

Inaugural grant awarded to the HealthTree Foundation, a pioneering non-profit organization whose proposal will address disparities in care in multiple myeloma PHILADELPHIA–(BUSINESS WIRE)–#Diversity–GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit organization helping patients learn more about … [Read more…]

TAE Life Sciences Showcases Targeted Drugs to Support Novel BNCT Accelerator System at 60th PTCOG Conference

FOOTHILL RANCH, Calif.–(BUSINESS WIRE)–TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today presented in vivo and in vitro boron delivery data using the company’s novel compounds at the 60th Particle Therapy Co-Operative Group (PTCOG) Conference, occurring June 27 – July 2, 2022. “The identification of these targeted … [Read more…]

Receptor Life Sciences Announces First Patient Dosed with RLS103 (Inhaled Dry Powder CBD) in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder

SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a clinical-stage pharmaceutical company developing innovative therapies to address central nervous system disorders, announced that the first patient has been dosed in its Phase 1b/2a clinical safety, tolerability, and efficacy study evaluating RLS103 in adult patients with acute anxiety within social anxiety disorder (SAD). RLS103, a dry powder inhaled cannabidiol … [Read more…]

IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders

GUAYNABO, Puerto Rico–(BUSINESS WIRE)–IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Dr. Richard L. Abbott and Dr. Lixin Xie. Dr. Abbott and Professor Xie join an established group of global advisors who will provide strategic insight and guidance to … [Read more…]

Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile

— STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents — — Approximately 3,400 patients per year diagnosed with NSCLC tumors that express EGFR with Exon 20 insertion mutations in the United States — — Preclinical data to … [Read more…]

 Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis

Phase III COMFORT™ study met its primary endpoint with statistically significant improvement and Piclidenoson had an excellent safety profile Can-Fite has licensing deals for the marketing of Piclidenoson for the treatment of Psoriasis in multiple global regions PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of … [Read more…]

btt Corp. Raises $29.3 Million to Deploy Diagnostic and Treatment Technologies Based on Brain Thermodynamics and Thermoregulatory Frequencies

World’s only brain-guided heat shock protein induction could help millions affected with neurologic disorders AVENTURA, Fla.–(BUSINESS WIRE)–btt Corp. (btt), a medical technology company focused on the development of innovative devices and treatments for targeted heat shock protein induction, today announced that Oklahoma Rock Holdings, LLC (Oklahoma Rock) has completed an investment of $29.3 million. btt’s … [Read more…]

Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger’s Novel Early Cancer Detection Platform

CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans … [Read more…]

Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market

RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities … [Read more…]

Vizient Announces Strategic Partnership with Supply Risk Solutions

Partnership enhances transparency between providers and suppliers IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. announced today it has entered into a strategic partnership with Supply Risk Solutions to provide a database platform for the collection of healthcare supply pedigree data. The partnership will provide automated supply chain disruption monitoring and risk prevention for Vizient members and is the … [Read more…]